Headlines | Finanzwire

Basculer en Français

8052	Companies
101123	Keywords
46327	Articles
57139	Press releases

BRIEF

published on 10/03/2024 at 22:22, 1 minute ago

Abrdn Asia-Pacific Income Fund Announces Series B Preferred Shares Issuance

Fixed Income Credit Rating Series B Shares Leverage Strategy Asia-Pacific Investment
PRESS RELEASE

published on 10/03/2024 at 22:17, 3 minutes ago

abrdn Asia-Pacific Income Fund, Inc. (FAX) Announces Issuance Of Series B Mandatory Redeemable Preferred Shares
abrdn Asia-Pacific Income Fund, Inc. announces the closing of a private offering of Series B MRPS. Fund's leverage strategy benefits income generation

Investment Abrdn Leverage Asia-Pacific Income Fund Series B MRPS
BRIEF

published on 10/03/2024 at 22:06, 13 minutes ago

Redcare Pharmacy Reports Significant Growth in Q3 Rx Sales

Customer Base Expansion Rx Sales Growth E-Rx Metrics Marketing Investment Non-Rx Sales
BRIEF

published on 10/03/2024 at 22:06, 14 minutes ago

Abivax recruits first patient for its clinical trial on Crohn's disease

Biotechnology Abivax Obefazimod Clinical Trial Crohn's Disease
BRIEF

published on 10/03/2024 at 22:02, 17 minutes ago

Redcare Pharmacy Announces Significant Growth in German Rx Sales for Q3

Financial Guidance Germany Redcare Pharmacy Rx Sales Growth E-Rx Metrics
PRESS RELEASE

published on 10/03/2024 at 22:01, 18 minutes ago

Redcare Pharmacy achieves 81% growth in Q3 Rx sales in Germany, 108% in September and decides to accelerate marketing based on very convincing e-Rx metrics.
Redcare Pharmacy achieves 81% growth in Q3 Rx sales in Germany and 108% in September, leading to accelerated marketing efforts based on strong e-Rx metrics. Full-year 2024 guidance updated for increased marketing activity

Sales Growth Redcare Pharmacy Q3 E-Rx Metrics Marketing Acceleration
PRESS RELEASE

published on 10/03/2024 at 22:01, 19 minutes ago

Abivax Announces First Patient Enrolled in ENHANCE-CD, the Phase 2b Trial of Obefazimod in Crohn’s Disease
Abivax announces enrollment of first patient in Phase 2b trial of Obefazimod for Crohn's Disease, aiming for convenient, effective treatment option with fewer daily burdens

Abivax Obefazimod Phase 2B Trial Immune Response Crohn's Disease
PRESS RELEASE

published on 10/03/2024 at 21:57, 22 minutes ago

EQS-Adhoc: Redcare Pharmacy achieves 81% growth in Q3 Rx sales in Germany, 108% in September and decides to accelerate marketing in Q4 based on very convincing e-Rx metrics. Full-year guidance updated.
Redcare Pharmacy achieves 81% growth in Q3 Rx sales in Germany, 108% in September. Full-year guidance updated with strategic decision to accelerate marketing in Q4 based on convincing e-Rx metrics

Marketing Germany Redcare Pharmacy Full-year Guidance Q3 Sales
BRIEF

published on 10/03/2024 at 21:40, 40 minutes ago

CFI Publishes its 2024 Half-Yearly Financial Report

Investors Financial Report 2024 Financial Markets CFI
BRIEF

published on 10/03/2024 at 21:05, 1 hour 15 minutes ago

Information on the share capital of FIDUCIAL REAL ESTATE

Share Capital Voting Rights Actions Fiducial Real Estate September 30, 2024

Accesswire

Published on 10/03/2024 at 22:17, 3 minutes ago

abrdn Asia-Pacific Income Fund, Inc. (FAX) Announces Issuance Of Series B Mandatory Redeemable Preferred Shares
Published on 10/03/2024 at 20:45, 1 hour 35 minutes ago

LQWD Reports Record Transaction Growth and Achieves #1 Rank on Lightning Terminal
Published on 10/03/2024 at 19:00, 3 hours 20 minutes ago

Last Call: Digitunity’s Connected Learning Award Program for Nonprofits Accepting Final Applications Until October 31
Published on 10/03/2024 at 18:10, 4 hours 10 minutes ago

Critical Elements Comments on Recent Market Activity
Published on 10/03/2024 at 17:00, 5 hours 20 minutes ago

EON Resources Inc.- Oil Production Increases

View all ACCESSWIRE

EQS Group

Published on 10/03/2024 at 22:01, 18 minutes ago

Redcare Pharmacy achieves 81% growth in Q3 Rx sales in Germany, 108% in September and decides to accelerate marketing based on very convincing e-Rx metrics.
Published on 10/03/2024 at 22:01, 19 minutes ago

Abivax Announces First Patient Enrolled in ENHANCE-CD, the Phase 2b Trial of Obefazimod in Crohn’s Disease
Published on 10/03/2024 at 21:57, 22 minutes ago

EQS-Adhoc: Redcare Pharmacy achieves 81% growth in Q3 Rx sales in Germany, 108% in September and decides to accelerate marketing in Q4 based on very convincing e-Rx metrics. Full-year guidance updated.
Published on 10/03/2024 at 20:00, 2 hours 20 minutes ago

Stabilisation Notice
Published on 10/03/2024 at 18:45, 3 hours 35 minutes ago

Fuller, Smith & Turner PLC: Transaction in own shares

Les Echos

Published on 10/03/2024 at 17:45, 4 hours 35 minutes ago

Aéroports de Paris SA - Voting rights as of 30 September 2024
Published on 10/03/2024 at 17:45, 4 hours 35 minutes ago

CHARGEURS - Voting rights monthly statement as of September 30th, 2024
Published on 10/03/2024 at 17:42, 4 hours 37 minutes ago

Mersen: Number of shares and voting rights as of September 30, 2024
Published on 10/03/2024 at 08:00, 14 hours 19 minutes ago

KURMA PARTNERS ACHIEVES FIRST CLOSE OF NEW EUR 250 MILLION BIOFUND IV
Published on 10/02/2024 at 18:50, 1 day 3 hours ago

AXA: Elimination of the dilutive impact of Shareplan 2024

View all LES ECHOS COMFI WIRE